CD5-positive diffuse large B-cell lymphoma

A retrospective study in 337 patients treated by chemotherapy with or without rituximab

K. Miyazaki, M. Yamaguchi, R. Suzuki, Y. Kobayashi, A. M. Maeshima, N. Niitsu, Daisuke Ennishi, J. I. Tamaru, K. Ishizawa, M. Kashimura, Y. Kagami, K. Sunami, H. Yamane, M. Nishikori, H. Kosugi, T. Yujiri, R. Hyo, N. Katayama, T. Kinoshita, S. Nakamura

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background: CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) shows poor prognosis and frequent central nervous system (CNS) relapses under anthracycline-containing chemotherapy. The aim of this study was to determine the prognosis and CNS relapse incidence of CD5+ DLBCL in the rituximab era. Patients and methods: We analyzed 337 patients with CD5+ DLBCL who received chemotherapy with (R-chemotherapy group; n = 184) or without (chemotherapy group; n = 153) rituximab. Results: No significant difference was found in clinical background comparisons between the two groups. In the R-chemotherapy group, 60% of the patients were older than 65 years at diagnosis. Both the complete response rate and overall survival (OS) were significantly better in the R-chemotherapy group (P = 0.0003 and P = 0.002, respectively). Multivariate analysis confirmed that chemotherapy without rituximab was associated with unfavorable OS. However, the probability of CNS relapse did not differ between the two groups (P = 0.89). The CNS relapse was strongly associated with short OS (P < 0.0001). In the R-chemotherapy group, 83% of patients who experienced CNS relapse had parenchymal disease. Conclusions: Our results indicate that rituximab improves the OS of patients with CD5+ DLBCL but does not decrease the CNS relapse rate. More effective treatments with CNS prophylaxis are needed for CD5+ DLBCL patients.

Original languageEnglish
Pages (from-to)1601-1607
Number of pages7
JournalAnnals of Oncology
Volume22
Issue number7
DOIs
Publication statusPublished - Jul 4 2011
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Retrospective Studies
Central Nervous System
Drug Therapy
Recurrence
Survival
Rituximab
Anthracyclines
Multivariate Analysis
Survival Rate
Incidence

Keywords

  • CD5
  • Central nervous system
  • Diffuse large B-cell lymphoma
  • Prognosis
  • Rituximab

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Miyazaki, K., Yamaguchi, M., Suzuki, R., Kobayashi, Y., Maeshima, A. M., Niitsu, N., ... Nakamura, S. (2011). CD5-positive diffuse large B-cell lymphoma: A retrospective study in 337 patients treated by chemotherapy with or without rituximab. Annals of Oncology, 22(7), 1601-1607. https://doi.org/10.1093/annonc/mdq627

CD5-positive diffuse large B-cell lymphoma : A retrospective study in 337 patients treated by chemotherapy with or without rituximab. / Miyazaki, K.; Yamaguchi, M.; Suzuki, R.; Kobayashi, Y.; Maeshima, A. M.; Niitsu, N.; Ennishi, Daisuke; Tamaru, J. I.; Ishizawa, K.; Kashimura, M.; Kagami, Y.; Sunami, K.; Yamane, H.; Nishikori, M.; Kosugi, H.; Yujiri, T.; Hyo, R.; Katayama, N.; Kinoshita, T.; Nakamura, S.

In: Annals of Oncology, Vol. 22, No. 7, 04.07.2011, p. 1601-1607.

Research output: Contribution to journalArticle

Miyazaki, K, Yamaguchi, M, Suzuki, R, Kobayashi, Y, Maeshima, AM, Niitsu, N, Ennishi, D, Tamaru, JI, Ishizawa, K, Kashimura, M, Kagami, Y, Sunami, K, Yamane, H, Nishikori, M, Kosugi, H, Yujiri, T, Hyo, R, Katayama, N, Kinoshita, T & Nakamura, S 2011, 'CD5-positive diffuse large B-cell lymphoma: A retrospective study in 337 patients treated by chemotherapy with or without rituximab', Annals of Oncology, vol. 22, no. 7, pp. 1601-1607. https://doi.org/10.1093/annonc/mdq627
Miyazaki, K. ; Yamaguchi, M. ; Suzuki, R. ; Kobayashi, Y. ; Maeshima, A. M. ; Niitsu, N. ; Ennishi, Daisuke ; Tamaru, J. I. ; Ishizawa, K. ; Kashimura, M. ; Kagami, Y. ; Sunami, K. ; Yamane, H. ; Nishikori, M. ; Kosugi, H. ; Yujiri, T. ; Hyo, R. ; Katayama, N. ; Kinoshita, T. ; Nakamura, S. / CD5-positive diffuse large B-cell lymphoma : A retrospective study in 337 patients treated by chemotherapy with or without rituximab. In: Annals of Oncology. 2011 ; Vol. 22, No. 7. pp. 1601-1607.
@article{9396a03648164c9db1930ac9cc502828,
title = "CD5-positive diffuse large B-cell lymphoma: A retrospective study in 337 patients treated by chemotherapy with or without rituximab",
abstract = "Background: CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) shows poor prognosis and frequent central nervous system (CNS) relapses under anthracycline-containing chemotherapy. The aim of this study was to determine the prognosis and CNS relapse incidence of CD5+ DLBCL in the rituximab era. Patients and methods: We analyzed 337 patients with CD5+ DLBCL who received chemotherapy with (R-chemotherapy group; n = 184) or without (chemotherapy group; n = 153) rituximab. Results: No significant difference was found in clinical background comparisons between the two groups. In the R-chemotherapy group, 60{\%} of the patients were older than 65 years at diagnosis. Both the complete response rate and overall survival (OS) were significantly better in the R-chemotherapy group (P = 0.0003 and P = 0.002, respectively). Multivariate analysis confirmed that chemotherapy without rituximab was associated with unfavorable OS. However, the probability of CNS relapse did not differ between the two groups (P = 0.89). The CNS relapse was strongly associated with short OS (P < 0.0001). In the R-chemotherapy group, 83{\%} of patients who experienced CNS relapse had parenchymal disease. Conclusions: Our results indicate that rituximab improves the OS of patients with CD5+ DLBCL but does not decrease the CNS relapse rate. More effective treatments with CNS prophylaxis are needed for CD5+ DLBCL patients.",
keywords = "CD5, Central nervous system, Diffuse large B-cell lymphoma, Prognosis, Rituximab",
author = "K. Miyazaki and M. Yamaguchi and R. Suzuki and Y. Kobayashi and Maeshima, {A. M.} and N. Niitsu and Daisuke Ennishi and Tamaru, {J. I.} and K. Ishizawa and M. Kashimura and Y. Kagami and K. Sunami and H. Yamane and M. Nishikori and H. Kosugi and T. Yujiri and R. Hyo and N. Katayama and T. Kinoshita and S. Nakamura",
year = "2011",
month = "7",
day = "4",
doi = "10.1093/annonc/mdq627",
language = "English",
volume = "22",
pages = "1601--1607",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - CD5-positive diffuse large B-cell lymphoma

T2 - A retrospective study in 337 patients treated by chemotherapy with or without rituximab

AU - Miyazaki, K.

AU - Yamaguchi, M.

AU - Suzuki, R.

AU - Kobayashi, Y.

AU - Maeshima, A. M.

AU - Niitsu, N.

AU - Ennishi, Daisuke

AU - Tamaru, J. I.

AU - Ishizawa, K.

AU - Kashimura, M.

AU - Kagami, Y.

AU - Sunami, K.

AU - Yamane, H.

AU - Nishikori, M.

AU - Kosugi, H.

AU - Yujiri, T.

AU - Hyo, R.

AU - Katayama, N.

AU - Kinoshita, T.

AU - Nakamura, S.

PY - 2011/7/4

Y1 - 2011/7/4

N2 - Background: CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) shows poor prognosis and frequent central nervous system (CNS) relapses under anthracycline-containing chemotherapy. The aim of this study was to determine the prognosis and CNS relapse incidence of CD5+ DLBCL in the rituximab era. Patients and methods: We analyzed 337 patients with CD5+ DLBCL who received chemotherapy with (R-chemotherapy group; n = 184) or without (chemotherapy group; n = 153) rituximab. Results: No significant difference was found in clinical background comparisons between the two groups. In the R-chemotherapy group, 60% of the patients were older than 65 years at diagnosis. Both the complete response rate and overall survival (OS) were significantly better in the R-chemotherapy group (P = 0.0003 and P = 0.002, respectively). Multivariate analysis confirmed that chemotherapy without rituximab was associated with unfavorable OS. However, the probability of CNS relapse did not differ between the two groups (P = 0.89). The CNS relapse was strongly associated with short OS (P < 0.0001). In the R-chemotherapy group, 83% of patients who experienced CNS relapse had parenchymal disease. Conclusions: Our results indicate that rituximab improves the OS of patients with CD5+ DLBCL but does not decrease the CNS relapse rate. More effective treatments with CNS prophylaxis are needed for CD5+ DLBCL patients.

AB - Background: CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) shows poor prognosis and frequent central nervous system (CNS) relapses under anthracycline-containing chemotherapy. The aim of this study was to determine the prognosis and CNS relapse incidence of CD5+ DLBCL in the rituximab era. Patients and methods: We analyzed 337 patients with CD5+ DLBCL who received chemotherapy with (R-chemotherapy group; n = 184) or without (chemotherapy group; n = 153) rituximab. Results: No significant difference was found in clinical background comparisons between the two groups. In the R-chemotherapy group, 60% of the patients were older than 65 years at diagnosis. Both the complete response rate and overall survival (OS) were significantly better in the R-chemotherapy group (P = 0.0003 and P = 0.002, respectively). Multivariate analysis confirmed that chemotherapy without rituximab was associated with unfavorable OS. However, the probability of CNS relapse did not differ between the two groups (P = 0.89). The CNS relapse was strongly associated with short OS (P < 0.0001). In the R-chemotherapy group, 83% of patients who experienced CNS relapse had parenchymal disease. Conclusions: Our results indicate that rituximab improves the OS of patients with CD5+ DLBCL but does not decrease the CNS relapse rate. More effective treatments with CNS prophylaxis are needed for CD5+ DLBCL patients.

KW - CD5

KW - Central nervous system

KW - Diffuse large B-cell lymphoma

KW - Prognosis

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=79959721309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959721309&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq627

DO - 10.1093/annonc/mdq627

M3 - Article

VL - 22

SP - 1601

EP - 1607

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -